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Abstract
Determining the optimal time interval between debulking surgery to adjuvant chemotherapy is crucial in
minimizing morbidity among ovarian cancer patients. A total of 43 operable ovarian cancer cases were
analyzed comparing between 2-week and 6-week interval. There were no signiﬁcant different in short term
morbidity between the groups. However the 2-week interval group had a better CA-125 reduction.
Background: The purpose of this study was to determine the effect of time interval between debulking surgery to
adjuvant chemotherapy on the short-term morbidity and carcinoma antigen (CA)-125 level. Patients and Methods: A
total of 43 patients with primary debulking surgery for operable stage epithelial ovarian cancer (stage IB to IIIC) from
January 2008 to January 2010 were analyzed prospectively. The participants were randomized into 2 groups. The
surgicalechemotherapy interval group 2 (SCI2) (n ¼ 22) received adjuvant chemotherapy (carboplatin and paclitaxel)
within 2 weeks after primary debulking surgery and the SCI6 (n ¼ 21) group received the same chemotherapy agents
6 weeks after the primary surgery. A computerized randomization technique was used. Results: Participants in the
SCI2 group had a better CA-125 reduction after 6 cycles of chemotherapy (P < .005) compared with the SCI6 group.
The incidence of anemia was more signiﬁcant in the SCI2 group (P < .005) than in the other group. However, there
were no signiﬁcant differences in wound breakdown, neutropenia, thrombocytopenia, and clinical response of
chemotherapy between the 2 groups. Conclusion: Time interval between primary surgery to the commencement of
adjuvant chemotherapy had no signiﬁcant effect on short-term morbidity, but had an improved effect on biochemical
(CA-125) response.
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Advanced epithelial ovarian cancer is the most lethal gyneco-
logical cancer. The prognosis corresponds well to the stage of
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http://dx.doi.org/10.1016/j.cogc.2013.12.005Obstetrics Annual Report 2006 postulated the 5-year survival rate
of 58.5% for stage IIIa, 39.9% for stage IIIb, 28.7% for stage IIIc,
and 16.8% for stage IV disease.1 Residual disease after initial sur-
gery,2 tumor grade,3 and histologic type4 are the most commonly
assessed variables to predict the response rate to chemotherapy and
survival outcome. Many other prognostic factors have been
described previously, which include age, performance status, and
carcinoma antigen (CA)-125 level. DNA ploidy, tumor suppressor
genes, oncogenes, and growth factors are relatively new prognosti-
cation factors for the disease.5-7
Previous studies reported a wide range of time interval from pri-
mary surgery to chemotherapy, from 3 to 62 days.5-10 In animal stu-
dies, perioperative chemotherapy and a short surgicalechemotherapy
interval resulted in an improved survival outcome.6-9 Theoretically,Clinical Ovarian and Other Gynecologic Cancer December 2013 - 25
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26 -tumor cells have greatest potential to grow after surgery, hence sup-
porting early adjuvant chemotherapy administration. Nevertheless,
results of some clinical trials have failed to support this theory.9,10
Conversely, there are sparse data to indicate beneﬁts with delayed
administration of adjuvant chemotherapy.10
Parallel to the worldwide cancer registry, the number of ovarian
carcinoma cases reported in our center is increasing with approxi-
mately 40 cases per year, with 80% of the cases being of epithelial
origin. The conventional ﬁrst-line chemotherapy agents for epithelial
ovarian cancer are platinum-based with a combination of taxane
agent. The ﬁrst cycle is usually commenced after the histopathological
report, which takes 3 to 6 weeks after surgery, depending on urgency.
Therefore, this study was aimed at determining the best time
interval for adjuvant chemotherapy after debulking surgery.
We considered the biochemical response (CA-125) consistent with
short-term morbidity based on the occurrence of bone marrow
suppression 11 and wound breakdown. The ﬁndings would beneﬁt
us in deciding the best time for adjuvant chemotherapy, to improve
the outcome and quality of life of ovarian cancer patients.
Patients and Methods
A prospective, nonblinded trial conducted in 2 gynecologic
oncology centers (Universiti Kebangsaan Malaysia Medical Centre,Figure 1 Study Flow Chart
Abbreviations: CA ¼ carcinoma antigen; CT ¼ computed tomography; FBC ¼ full blood count; SC
Clinical Ovarian and Other Gynecologic Cancer December 2013Malaysia and Hasanuddin Medical Centre, Makassar, Indonesia).
We hypothesized a longer interval from surgery to chemotherapy
would be associated with less short-term morbidity. Eligibility
criteria involved operable stage ovarian cancer, epithelial in origin,
participants who required adjuvant chemotherapy after surgery and
not contraindicated for carboplatin and taxane agents. University
hospital ethics committee approval was obtained before the start
of this study.
Eligible participants were recruited after informed consent.
Randomization was performed using a computer program and
sample size was calculated using StatCal software version 3.0, with
42 samples required for 80% power and P value of < .05.
Participants were randomized into a surgicalechemotherapy
interval of 2 weeks (SCI2) and surgicalechemotherapy interval of
6 weeks (SCI6) (Fig. 1). They received the ﬁrst cycle of chemo-
therapy 2 weeks and 6 weeks after the surgery, respectively.
Baseline preoperative investigations included full blood count,
CA-125, and computed tomography (CT) scan of the thorax,
abdomen, and pelvis performed before staging and debulking
surgery by the designated gynecologic oncologists’ team. The
removed specimen was sent for histopathological conﬁrmation.
Adjuvant chemotherapy consisting of 6 cycles of paclitaxel (175
mg/m2) and carboplatin (area under the curve [AUC] 5) wasI ¼ surgicalechemotherapy interval.
Table 1 Characteristics of Tumors
Characteristic
SCI2 (n [ 22),
n (%)
SCI6 (n [ 21),
n (%) P
FIGO Classiﬁcation
1c 11 (50.0) 8 (38.1) .097a
2a 3 (13.6) 0 (0)
2b 1 (4.5) 0 (0)
2c 0 (0) 4 (19)
3a 4 (18.2) 4 (19)
3b 1 (4.5) 0 (0)
3c 2 (9.1) 5 (23.8)
Histopathology
Serous 8 (36.4) 7 (33.3) .148a
Mucinous 4 (18.2) 2 (9.5)
Endometroid 10 (45.5) 9 (42.9)
Clear-cell 0 (0) 2 (9.5)
Brenner 0 (0) 1 (4.8)
Ascites
Present 18 (81.8) 11 (52) .065a
Not present 4 (18.2) 10 (47.6)
CA-125 Level
(Preoperative)
336 (203,631) 333 (68.5704) .618b
Abbreviations: CA ¼ carcinoma antigen; FIGO ¼ International Federation of Gynaecology and
Obstetrics; SCI ¼ surgicalechemotherapy interval.
aPearson c2 test.
bMann Whitney U Test.
Mohamad Nasir Shaﬁee et aladministered with 3 weekly intervals between the cycles as per
local protocol.
The outcome measures include short-term morbidity (morbidity
occurring within 6 months of chemotherapy which involved wound
breakdown and myelosuppression), response to treatment (CA-125
reduction, clinical and imaging [CT scan] evidence of disease), and
performance status.12
The Eastern Cooperative Group/World Health Organization
(WHO) Performance Status Scale deﬁnes: 0 ¼ normal activity, no
restrictions; 1 ¼ restricted but ambulatory (able to carry out light
work); 2 ¼ ambulatory and able to perform self-care but unable
to carry out light work for more than 50% of waking hours; 3 ¼
limited self-care and conﬁned to bed or chair more than 50% of
waking hours; and 4 ¼ completely disabled/totally conﬁned to
bed/might need admission to hospital.12
After completion of the sixth cycle of chemotherapy, participants
with no evidence of persistence or local recurrence were categorized
as complete clinical response.
Data were analyzed using SPSS Version 19.0. The Pearson c2
test was used to compare the frequencies of the prognostic factors
and chemotherapy in the respective groups (SCI2 and SCI6). The
nonparametric correlation between time intervals from primary
surgery to the ﬁrst cycle of chemotherapy was calculated using the
Spearman rank correlation coefﬁcient.
Results
A total of 43 participants with epithelial ovarian carcinoma were
recruited in this study. The median ages of participants were 50
and 56 years in SCI2 and SCI6, respectively, and not statistically
signiﬁcant (P ¼ .059). Most of them were classiﬁed according
to the American Society of Anesthesiologists as score 1 (25 of
43 participants).
Stage 1C was the highest proportion in SCI2 and SCI6, 11
patients (50%) and 8 patients (38.1%), respectively. However,
using Pearson c2 test, there was no signiﬁcant difference between
the stage of the cancer in these 2 groups (P ¼ .097). Endomet-
roid adenocarcinoma was the most common subtype followed by
serous and mucinous adenocarcinoma, but subtype differences
were not statistically signiﬁcant between the 2 groups (P ¼ .148).
Preoperative CA-125 level was comparable in the SCI2 and SCI6
groups, with 336 U/mL (range, 203-631 U/mL) and 333 U/mL
(range, 68.5-704 U/mL), respectively. The ﬁndings are sum-
marized in Table 1.
Wound breakdown was not shown to be increased in SCI2 (3 of
22 participants) and SCI6 (2 of 21 participants). There was a sig-
niﬁcant difference in median total white cell count between the
2 groups after the third and sixth cycle of chemotherapy (P < .05).
However, only 1 case of neutropenia occurred in the study popu-
lation, which was not a signiﬁcant ﬁnding. The median platelet
counts in the SCI2 group were signiﬁcantly less compared with
the SCI6 group after the third and sixth cycle of chemotherapy
(P < .05), but the incidence of thrombocytopenia in both groups
was not statistically signiﬁcant (Table 2). After the third cycle of
chemotherapy, there was a signiﬁcant decrease of hemoglobin in
the SCI2 group with a median value of 9 g/dL (95% conﬁdence
interval [CI], 8.9-9.5) versus 10.5 g/dL (95% CI, 9.8-11.25) in the
SCI6 group (Fig. 2).Response to treatment was observed using biochemical markers
and performance status. Biochemical response was assessed ac-
cording to a 50% reduction of serum CA-125 level after completion
of the fourth and sixth cycles of chemotherapy.13 It was shown to be
signiﬁcantly improved in the SCI2 group at the fourth and sixth
cycle of chemotherapy (P < .001). There was no signiﬁcant dif-
ference in clinical response and rate of recurrence in both groups
(Table 3).
Discussion
Advanced stage ovarian cancer has a dismal outcome with an
overall 5-year survival rate of approximately 35%.12 The prognostic
factors for ovarian cancer include tumor stage, grade of tumor dif-
ferentiation, tumor volume, and histological subtypes.14 A new
model to prognosticate early-stage ovarian cancer was designed,
which used a combination of age, grade and stage of the tumor,
lymphadenectomy, and chemotherapy use. At a cutoff value of 211
for prognostic index, the low- and high-risk groups of recurrence
within 5 years were identiﬁed.14
Various strategies are being implemented to improve clinical
outcomes in ovarian cancer. These include a proper referral to the
designated gynecologic oncology centers that are equipped with
adequate facilities and expertise, adherence to revised guidelines
and protocols, and evidence-based recommendations to improve the
standard of care.15 Because most ovarian cancers are chemosensitive,
cytoreduction followed by chemotherapy consisting taxane and
platinum-based agents represent a standard treatment regime for
epithelial ovarian cancers. Carboplatin and paclitaxel thus haveClinical Ovarian and Other Gynecologic Cancer December 2013 - 27
Table 2 Short-Term Morbidity
Event SCI2 (n [ 22) SCI6 (n [ 21) P
Wound Breakdown 3 (13.6) 2 (9.5) 1.000a
Myelosuppression
Neutropenia
WCC third cycle after chemotherapy 7.8 (6.0-8.4) 3.7 (3.25-5.00) .001b
Neutropenia third cycle after chemotherapy 0 (0) 1 (4.8) .981a
WCC sixth cycle after chemotherapy 7.2 (6.6-8.0) 3.7 (3.10-5.70) <.001b
Neutropenia sixth cycle after chemotherapy 0 (0) 0 (0) e
Thrombocytopenia
Platelet third cycle after chemotherapy 131 (119-164) 235 (145-283) .001b
Thrombocytopenia third cycle after chemotherapy 3 (13.6) 1 (4.8) .634a
Platelet sixth cycle after chemotherapy 120 (109-138) 193 (133-271) <.001b
Thrombocytopenia sixth cycle after chemotherapy 2 (9.09) 3 (14.2) .956a
Anemia
Hb before chemotherapy 10.6 (10.0-11.0) 11.6 (10.2-12.3) .001c
Hb third cycle after chemotherapy 9.0 (8.9-9.5) 10.5 (9.8-11.2) .001b
Anemia third cycle after chemotherapy 20 (90.9) 7 (33.3) <.001c
Hb sixth cycle after chemotherapy 9.4 (9.2-10.0) 9.6 (9.0-10.1) .779b
Anaemia sixth cycle after chemotherapy 16 (72.2) 15 (71.4) .924c
Data are presented as n (%) or median (interquartile range).
Abbreviation: Hb ¼ hemoglobin; SCI ¼ surgicalechemotherapy interval; WCC ¼ white cells count.
aContinuity correction (Yates correction).
bMann Whitney U Test.
cPearson c2 test.
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28 -widespread acceptance as initial chemotherapy for ovarian cancer
because of less risk of nephrotoxicity and neurotoxicity.16
Nevertheless, the controversial issue pertaining the optimal
duration interval between primary surgery to commencement of
chemotherapy is still inconclusive. There are scarce data on effec-
tiveness of adjuvant chemotherapy after primary debulking surgery
in animal models.12,14 A cohort study by Warwick et al, which
included 362 patients with advanced disease, showed a poorerFigure 2 Hemoglobin Trend Before Chemotherapy, After the
Third Cycle, and After Completed Chemotherapy
Abbreviations: SCI ¼ surgicalechemotherapy interval; SCI 2 ¼ 2-week surgical to chemo-
therapy interval; SCI 6 ¼ 6-week surgical to chemotherapy interval.
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based agents. However, the interval was not an independent prog-
nostic factor in multivariate analysis.15
Another study by Flynn et al, which represents The Scottish
Gynaecological Cancer Trials Groups 2002, investigated the time
interval between primary surgery to chemotherapy (combination of
a platinum-based agent and taxane) on the effect of disease-free
survival of 472 patients revealed a median interval of 22 days
with range of 5 to 113 days. Further analysis found a worse
progression-free survival for patient with a shorter interval. How-
ever, the drawback of this study was an equivocal selection of
bulkier residual disease for early adjuvant chemotherapy.17
Gadducci et al investigated the clinical relevance of time interval
from primary surgery to chemotherapy in 315 patients with
advanced epithelial ovarian cancer who had been given taxane plus
platinum-based chemotherapy with intervals of 11 days, 21 days,
and 31 days. However, statistical analysis failed to prove any sig-
niﬁcant differences in complete response and survival rate among
the samples.9
A total of 43 epithelial ovarian cancer patients were randomized
in our study for a 2-week chemotherapy interval (SCI2) with
platinum and taxane chemotherapy versus a 6-week interval (SCI6)
after primary debulking surgery. The major concern encompassed
on short-term morbidity included wound breakdown and myelo-
suppression (neutropenia, anemia, and thrombocytopenia). There
were no signiﬁcant differences in wound breakdown (P ¼ 1.000),
neutropenia, and thrombocytopenia in the SCI2 and SCI6 groups
after the third and sixth cycles of chemotherapy. However,
the baseline level of white cells count in the SCI6 group was
Table 3 Response to Treatment
Type of Response SCI2 (n [ 22), n (%) SCI6 (n [ 21), n (%) P Values
Biochemical Response (Reduction of CA-125 Level)
After chemotherapy third cycle 4 (18) 3 (14) 1.000a
After chemotherapy fourth cycle 21 (95.5) 4 (19.0) <.001b
After chemotherapy sixth cycle 21 (95.5) 9 (42.9) <.001b
Clinical Response (Performance Status)
After chemotherapy third cycle
Good response 21 (95.5) 20 (95.2) 1.000a
Slow response 1 (4.5) 1 (4.8)
After chemotherapy sixth cycle
Good response 19 (86.4) 20 (95.2%) .634a
Slow response 3 (13.6) 1 (4.8)
Radiological (Rate of Cancer Recurrence) 1 (4.7) 2 (9) .967a
Abbreviations: CA ¼ carcinoma antigen; SCI ¼ surgicalechemotherapy interval.
aContinuity correction (Yates correction).
bPearson c2 test.
Mohamad Nasir Shaﬁee et alsigniﬁcantly less than in the SCI2 group after the third and sixth
cycle of chemotherapy (P ¼ .01 vs. P < .01). In contrast, the
baseline platelet level was improved in the SCI6 group compared
with the SCI2 group after the third and sixth cycle of chemo-
therapy. We postulated a possibility of hematological recovery after
blood loss during major surgery. Unfortunately, this parameter was
not assessed in this study. The only supported evidence was the
greater incidence of anemia in the SCI2 group compared with the
SCI6 group after the third cycle of chemotherapy (90.9% vs. 33%,
respectively) with a P value of .01. Nevertheless, the hemoglobin
level improved at the completion of the sixth cycle in the SCI2
group, comparable with the SCI6 group with no signiﬁcant dif-
ference (P > .05). A retrospective multicenter study analyzed he-
moglobin level before the start of ﬁrst-line taxane/platinum-based
chemotherapy in 315 participants with advanced ovarian cancer
found that hemoglobin levels were not an independent prognostic
factor for overall survival rate.9
Clinical response was assessed using a standard WHO perfor-
mance status scale, mentioned herein. In this study, we found that
there were no signiﬁcant differences in clinical response and per-
formance status of patients after chemotherapy in the SCI2 group
and the SCI6 group (P ¼ .64). A previous retrospective study was
performed to predict early morbidity at 30 days after debulking
surgery in ovarian cancer, particularly aimed at the patient’s age,
performance status, duration, and extent of surgery. It was reported
that WHO performance status was signiﬁcantly better in the group
of patients with an uncomplicated postoperative course (P ¼
.043).18 However, the median age of participants was 64 years with
31% aged older than 70 years. Therefore, it is difﬁcult to conclude
whether early chemotherapy (2-week interval) might further
complicate the preexisting morbidity.
Biochemical response, assessed by observing the tumor marker
trend (CA-125) before and after chemotherapy, was either a 50%
reduction of CA-125 in 4 consecutive readings or a 75% reduction
of CA-125 in 3 consecutive readings.13 There was a slight reduction
of CA-125 level between the 2 groups after the third cycle of
chemotherapy (P ¼ 1.000). However, after the completed sixthcycle of chemotherapy, participants in the SCI2 group showed a
better reduction in CA-125 level compared with participants in the
SCI6 group (P < .001). This result showed that early commence-
ment of chemotherapy will improve response to treatment and
survival as reported in animal models.12,14 Even though CA-125 has
a poor sensitivity of 35% in monitoring chemotherapy response
in ovarian cancer, and it failed to demonstrate any reliable cutoff
point value, it is the most commonly used blood parameter. It
was statistically found that 20% of the chemotherapy responders
will be identiﬁed as nonresponders (P ¼ .025) in a single study.19
A more recent analysis determined the efﬁcacy of CA-125 AUC
at different stages of epithelial ovarian cancer to prognosticate
the overall survival found that the CA-125 level persistently corre-
lated with the disease stage.20 After the minimum of 3 cycles of
chemotherapy (carboplatin and taxol), the median CA-125 was
42.5 (stage I), 58.06 (stage II), 54.6 (stage III), and 149.3 IU/mL
(stage IV) (P ¼ .004).20 A level of 99.75 IU/mL CA-125 had a
sensitivity of 90.9% with 1.27 as a positive likelihood ratio to
predict 5-year survival rate.20 Radiological response to treatment
was assessed by performing a CT scan at the third cycle after
chemotherapy and after the completed sixth cycle after chemo-
therapy. In this study, there were no signiﬁcant differences in rates
of recurrence in both groups with 4.7% in the SCI2 group and 9%
in the SCI6 group.Conclusion
We conclude that using the shorter surgicalechemotherapy in-
terval, the better clinical response is expected without jeopardizing
short-term morbidity and patient performance status. Minimization
of blood loss at surgery and optimization of hemoglobin level before
the start of adjuvant chemotherapy might reduce the incidence of
anemia after chemotherapy.
Clinical Practice Points
 The role of adjuvant chemotherapy following debulking surgery
in epithelial ovarian cancer is well understood.Clinical Ovarian and Other Gynecologic Cancer December 2013 - 29
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30 - Pertinent issue in determining the best optimal time to
commence the chemotherapy is yet to be established.
 Postoperative morbidity and chemotherapy effects are the issues
that likely to inﬂuence the decision to start on the chemotherapy.
 The 2-week interval between surgery to adjuvant chemotherapy
resulted in better CA-125 reduction, without contributing to
higher short term morbidity.
 However the recurrence and the overall survival rate are the other
issues that need to be looked at in the future research.
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